Safety profile of EGFR-targeted hybrid vector system composed of PAMAM dendrimer and oncolytic adenovirus

We would like to thank Huang et al. for comments on our recent report, which assessed the “antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with epidermal growth factor receptor (EGFR)-targeted poly(amidoamine) (PAMAM)-based dendrimer (1)”. We read the comments with great interest and acknowledging that this is an area urgently requiring more research to improve safety of nanomaterials in gene therapy for clinical application.